BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Kelly Shi does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 VSTMVerastem Inc | Buy | $15.00 | Apr 2025 | +4.9% | Miss |
 TILInstil Bio Inc. | Buy | $52.00 | Jan 2025 | −83.1% | Miss |
 FHTXFoghorn Therapeutics Inc | Buy | $14.00 | Dec 2024 | −31.3% | Miss |
| FHTXFoghorn Therapeutics Inc | Buy | $18.00 | Sep 2024 | −22.8% | Miss |
 ARTVArtiva Biotherapeutics, Inc. Common Stock | Buy | $21.00 | Aug 2024 | −66.0% | Miss |
 PROKProKidney Corp. | Buy | $6.00 | Jun 2024 | −52.9% | Miss |
| PROKProKidney Corp. | Buy | $15.00 | Dec 2022 | −74.3% | Miss |
 GLUEMonte Rosa Therapeutics Inc | Buy | $20.00 | Aug 2022 | −34.5% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.